News|Podcasts|January 9, 2024
Prioritizing R&D Initiatives to Support Cell Line Development
Author(s)AGC Biologics
Robust, scalable manufacturing of novel therapeutics requires partnering with a CDMO equipped to adapt to changes in the market and knowledgeable on the latest technologies used to support cell line development.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
2
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
3
How Mitigation and Maintenance Protect Against Future Risk
4
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
5
